Evolus Inc (EOLS)vsZoetis Inc (ZTS)
EOLS
Evolus Inc
$7.64
+3.60%
HEALTHCARE · Cap: $488.77M
ZTS
Zoetis Inc
$77.80
-0.55%
HEALTHCARE · Cap: $32.80B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 2910% more annual revenue ($9.53B vs $316.49M). ZTS leads profitability with a 27.7% profit margin vs -10.8%. ZTS earns a higher WallStSmart Score of 58/100 (C).
EOLS
Avoid34
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.5%
Fair Value
$14.59
Current Price
$7.63
$6.96 discount
Margin of Safety
+10.3%
Fair Value
$143.36
Current Price
$77.80
$65.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 21.2% year-over-year
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18730.0% — below average capital efficiency
Trading at 10.2x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : EOLS
The strongest argument for EOLS centers on Debt/Equity, Revenue Growth. Revenue growth of 21.2% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : EOLS
The primary concerns for EOLS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
EOLS profiles as a growth stock while ZTS is a declining play — different risk/reward profiles.
EOLS carries more volatility with a beta of 1.34 — expect wider price swings.
EOLS is growing revenue faster at 21.2% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 34/100), backed by strong 27.7% margins. EOLS offers better value entry with a 70.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evolus Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?